SNX3-IN-1
SNX3-IN-1 is a sorting nexin 3 (SNX3) inhibitor. SNX3-IN-1 reduces SNX3 protein expression and inhibits SNX3-mediated activation of the Wnt/β-catenin signaling pathway. SNX3-IN-1 inhibits the proliferation and migration of pulmonary fibrosis-related cells, and decreases the expression of fibrosis markers α-SMA and COL-1. SNX3-IN-1 can be used in research related to pulmonary fibrosis.
For research use only. We do not sell to patients.
- CAS No.: 2344793-72-0
- Formula: C23H24O6
- Molecular Weight:396.43
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
SNX3-IN-1 (Compound LC4) inhibits the enhanced migratory capacity of fibroblasts overexpressing SNX3[1].
SNX3-IN-1 inhibits SNX3-induced β-catenin accumulation and nuclear localization in cells[1].
SNX3-IN-1 (10 μM) inhibits TGF-β1-induced α-SMA expression in AT2 cells and fibroblasts, thereby reducing fibrotic activation[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6J Snx3-cTg mice (2 months old, male and female; spontaneous pulmonary fibrosis model); C57BL/6J N-Tg mice (2 months old, male and female; bleomycin-induced pulmonary fibrosis model)[1]
-
Dosage:10 mg/kg
-
Administration:intratracheal; once weekly; 3 weeks
-
Result:Mitigated Bleomycin (BLM) (HY-108345)-induced pulmonary functional injury, reduced fibrosis areas, lowered β-catenin protein levels, and decreased hydroxyproline concentration in N-Tg mice.
Reversed fibrotic effects associated with SNX3 overexpression in Snx3-cTg mice, including reducing lung injury, fibrosis areas, and β-catenin levels.
Demonstrated therapeutic efficacy equivalent to positive control pirfenidone in inhibiting BLM-induced pulmonary fibrosis.
Chemical Information
-
CAS No. 2344793-72-0
-
Molecular Weight 396.43
-
Formula C23H24O6
-
SMILES
O=C(C1=CC=C(OCC)C=C1O/2)C2=C\C3=CC(C)=C(OC(C)(C(O)=O)C)C(C)=C3
-
Sequence
Arg-His-Arg-Thr-Pro-Met-Phe-Tyr-Gly-Leu-Met-NH2
-
Sequence Shortening
RHRTPMFYGLM-NH2
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
SNX3-IN-1 Related Classifications
HY-181439 Related Classifications
Powered by Bioz